- Innate Pharma SA’s (NASDAQ:IPHA) futility interim analysis of the INTERLINK-1 Phase 3 study sponsored by AstraZeneca Plc (NASDAQ:AZN) did not meet a pre-defined threshold for efficacy.
- Based on this result and the recommendation of an Independent Data Monitoring Committee, AstraZeneca has informed Innate that the study will be discontinued.
- There were no new safety findings. AstraZeneca plans to share the data in due course.
- Related: Innate Pharma Says Chemo-Free Monalizumab Triplet Therapy Shows Preliminary Anti-Cancer Activity.
- The INTERLINK-1 study evaluated monalizumab in combination with cetuximab vs. cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
- Monalizumab is being studied in a Phase 3 study sponsored by AstraZeneca, evaluating durvalumab in combination with monalizumab or AstraZeneca’s oleclumab (anti-CD73) in patients with unresectable, Stage III non-small cell lung cancer.
- Price Action: IPHA shares are down 16.3% at $2.68 during the premarket session on the last check Monday.
AstraZeneca Cuts Innate-Partnered Phase 3 Trial In Head & Neck Cancer
Innate Pharma SA’s (NASDAQ:IPHA) futility interim analysis of the INTERLINK-1 Phase 3 study sponsored by AstraZeneca Plc (NASDAQ:AZN) did not meet a…
Related Posts
Amyris Reports Q1 2023 Revenue; Sees Q1 Revenue ~$56M Vs $50M Previously Issued Guidance Delivered In Q4
Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty
What’s Going On With Archer Aviation Stock After Q1 Earnings?
Archer Aviation reported quarterly losses of 36 cents per share which missed the analyst consensus estimate of losses of 35 cents by 2.86%. The company reported a net loss for the first quarter of 2024 of $116.5 million. Archer said the loss represents investments required to achieve the key elements of its commercialization plan, including continued investment in the design, development, test and certification activities for its Midnight aircraft.
Why Hasbro Stock Popped Today
Hasbro, Inc. (NASDAQ: HAS) shares traded higher Tuesday after a B of A Securities analyst raised its price target on the stock.